Department of antitumor drug therapy
The Department of Antitumor Drug Therapy of the NMRC of Oncology named after N.N. Petrov provides conventional and advanced systemic antitumor therapy for patients with disseminated solid tumors.
The department specializes in the treatment of malignant tumors across various sites, including:
- skin melanoma
- germ cell tumors (seminoma, non-seminoma, germinoma, dysgerminoma)
- bone and soft tissue sarcomas (osteosarcoma, Ewing's sarcoma, chondrosarcoma, liposarcoma, leiomyosarcoma, schwannoma, malignant fibrous histiocytoma, and others)
- colorectal cancer
- gastric (stomach) cancer
- lung cancer (small cell lung cancer and non-small cell lung cancer)
- neuroendocrine tumors (carcinoid tumors, neuroendocrine carcinomas, apudomas, etc.)
- breast cancer
- ovarian cancer
- endometrial cancer
- renal (kidney) cancer
- prostate cancer
- bladder cancer
- and other solid malignancies
Treatment modalities offered:
- chemotherapy — including polychemotherapy, high-dose chemotherapy, and prolonged infusion of cytostatic drugs
- immunotherapy — utilizing cytokines (IL-2, alpha-IFN), immune checkpoint inhibitors, and antitumor vaccines
- targeted therapy
- hormone therapy
- «Antitumor Drug Therapy: Chemotherapy» (PDF, 4.9 MB)
- «Antitumor Drug Therapy: Immunotherapy» (PDF, 1.6 MB)
The department conducts clinical trials investigating innovative and promising antitumor drugs and treatment modalities. For decades, our team has been advancing therapeutic approaches for malignant neoplasms, incorporating the latest breakthroughs in global oncology research.
The Department of Antitumor Drug Therapy serves as the primary clinical base for the Cancer Immunology Research Division at the NMRC of Oncology named after N.N. Petrov. The department's physicians are nationally and internationally recognized experts in immunotherapy, a field they have been developing since 1998. They continue to research and implement innovative immunotherapeutic approaches, with a particular focus on antitumor vaccines. To date, they have successfully developed 15 novel antitumor vaccines and related technologies.
The specialists in the Department of Antitumor Drug Therapy collaborate closely with the Center's surgical teams to provide treatment for prostate, bladder, ovarian, endometrial, and breast cancers.
The department's clinical team are recognized experts in the management of cutaneous melanoma, germ cell tumors, and both soft tissue and bone sarcomas.
As thought leaders in the field, the department’s team actively contributes to developing national treatment guidelines for malignant neoplasms, helping to shape oncology practice standards across the country.
The department is led by ТDr. Gulfia M. Teletaeva, Candidate of Medical Sciences.
The department's team consists of highly qualified specialists who are active members of the world's leading professional oncology associations, including:
- Russian Society of Clinical Oncology (RUSSCO)
- American Society of Clinical Oncology (ASCO)
- European Society for Medical Oncology (ESMO)
- European Association of Dermato-Oncology (EADO)
- Eurasian Federation of Oncologists (EAFO)